Media & Press Updates
Pluristyx in the News
Pluristyx to participate and present at PDA Annual Meeting
March 12, 2019
Dr. Brian Hawkins, CTO of Pluristyx, will present, "Phase-Appropriate Application of Biopreservation: Best Practices to Support Regenerative Medicine Advanced Therapy Commercialization," in the Disruptive Technologies Session at the 2019 Parenteral Drug Association Annual Meeting in San Diego, CA. The seminar will focus on the importance of optimized cryopreservation protocols in both autologous and allogenic cell therapy product development, with particular emphasis on creation of the Master Cell Bank. Dr. Hawkins will also participate in PDA governance as a member of the Biopharmaceutical Advisory Board and as President-elect of the Pacific Northwest Chapter of the PDA.
Pluristyx takes the lead in Cell Therapy Standards Development
March 18, 2019
Dr. Brian Hawkins, CTO of Pluristyx, is team leader for the ANSI/PDA standard initiative entitled, "Cryopreservation of Cells for Use in Cell Therapies and Regenerative Medicine Manufacturing." This initiative aims to establish recommendations and guidelines for the freezing of cells for clinical use to speed regenerative medicine advanced therapy (RMAT) product development. As a recognized leader in RMAT standards development, Dr. Hawkins will be participating and presenting at a National Institutesof Standards and Technology (NIST) workshop jointly sponsored by NIST, the US Food and Drug Administration (FDA), the Standards Coordinating Body (SCB), and Nexight Group. Dr. Hawkins will be interviewed and featured in a report on the current state of cell therapy standards published by the Nexight Group.
Pluristyx technology platform featured in webinar
February 27, 2019
Prepare for success: GMP cell banks as part of a staged, standardized, platform-style cell production process
Dr. Ben Fryer, Co-Founder and CEO of Pluristyx, presented to webinar participants the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and the manufacturing workflow, beginning with the starting cell source and Master Cell Bank.
